ArticleDrug target insights2016
Preliminary In Vivo Evaluation of a Hybrid Armored Vascular Graft Combining Electrospinning and Additive Manufacturing Techniques.
Article in Drug target insights, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Percutaneous versus Surgical Intervention for Severe Aortic Valve Stenosis: A Systematic Review.BioMed research international · 2021Pooled it
- External Scaffold for Strengthening the Pulmonary Autograft in the Ross Procedure.Biomimetics (Basel, Switzerland) · 2024Review
- Enhancing decellularized vascular scaffolds with PVDF and PCL reinforcement: a fused deposition modeling approach.Frontiers in cardiovascular medicine · 2023Article
- Acellular Tissue-Engineered Vascular Grafts from Polymers: Methods, Achievements, Characterization, and Challenges.Polymers · 2022Review
- Biomechanics of Transcatheter Aortic Valve Implant.Bioengineering (Basel, Switzerland) · 2022Review
- Structural Heart Valve Disease in the Era of Change and Innovation: The Crosstalk between Medical Sciences and Engineering.Bioengineering (Basel, Switzerland) · 2022Article
- Vascular implants - new aspects for in situ tissue engineering.Engineering in life sciences · 2022Review
- Review
- Novel reinforcement of corrugated nanofiber tissue-engineered vascular graft to prevent aneurysm formation for arteriovenous shunts in an ovine model.JVS-vascular science · 2022Article
- The Use of Bioactive Polymers for Intervention and Tissue Engineering: The New Frontier for Cardiovascular Therapy.Polymers · 2021Review
- Biomechanical future of the growing pulmonary autograft in Ross operation.Translational pediatrics · 2020Review
- Gene therapy and regenerative tissue engineering in congenital heart disease.Translational pediatrics · 2019Article
- The use of allogenic and autologous tissue to treat aortic valve endocarditis.Annals of translational medicine · 2019Review
- Targeted Delivery of Bioactive Molecules for Vascular Intervention and Tissue Engineering.Frontiers in pharmacology · 2018Review
- Additive Manufacturing of Vascular Grafts and Vascularized Tissue Constructs.Tissue engineering. Part B, Reviews · 2017Review
- Delivery of Antioxidant and Anti-inflammatory Agents for Tissue Engineered Vascular Grafts.Frontiers in pharmacology · 2017Review
- CURRENT DEVELOPMENTS IN DRUG ELUTING DEVICES: Introductory Editorial: Drug-Eluting Stents or Drug-Eluting Grafts? Insights from Proteomic Analysis.Drug target insights · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we tested in vivo effectiveness of a previously developed poly-l-lactide/poly-ε-caprolactone armored vascular graft releasing heparin. This bioprosthesis was designed in order to overcome the main drawbacks of tissue-engineered vascular grafts, mainly concerning poor mechanical properties, thrombogenicity, and endothelialization. The bioprosthesis was successfully implanted in an aortic vascular reconstruction model in rabbits. All grafts implanted were patent at four weeks postoperatively and have been adequately populated by endogenous cells without signs of thrombosis or structural failure and with no need of antiplatelet therapy. The results of this preliminary study might warrant for further larger controlled in vivo studies to further confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.